Yasugi Akiko, Yashima Kazuo, Hara Akihito, Koda Masaharu, Kawaguchi Koichiro, Harada Kenichi, Andachi Hironobu, Murawaki Yoshikazu
Division of Medicine and Clinical Science, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan.
Oncol Rep. 2008 Jan;19(1):41-7.
There are two different pathways for the development of colorectal carcinoma (CRC), adenoma-carcinoma sequence (ACS) and de novo (DN) carcinogenesis. To clarify the molecular and clinicopathological characteristics in colorectal carcinogenesis, we examined endoscopically resected specimens of 30 adenomas, 30 carcinoma in adenomas (CIAs), and 18 early pure colorectal carcinomas without any adenoma component (EPCs, so called DN carcinoma) and compared the expression of Fhit, Mlh1, Msh2, P53 and cellular phenotype (HGM, MUC2 and CD10). Markedly reduced or absent Fhit expression was noted in 8 (44%) of 18 EPCs, but none of the adenomas or CIAs (p<0.0001). Six (33%) of 18 EPCs showed loss of Mlh1 expression, but rarely in adenomas and CIAs (p=0.008). This altered Fhit expression was significantly higher in submucosal invasive cancers (p=0.001), lymphatic or venous invasive cancers (p=0.0018), and tumors with altered expression of Mlh1 (p=0.01). The incidence of P53 overexpression was significantly higher in EPCs (39%) and CIAs (27%) than in adenomas (3.3%) (p<0.05). There were significant differences in phenotypic expression between the adenomatous and carcinomatous areas. Moreover, in CIAs and EPCs, the rate of P53 overexpression was significantly higher in the CD10-positive cases (53%) than CD10-negative cases (19%) (p=0.04). The present findings suggested that aberrant Fhit and Mlh1 expression could be related to DN carcinogenesis and that P53 overexpression and changes in phenotypic expression could contribute to the malignant transformation of colorectal precursor lesions.
结直肠癌(CRC)的发生有两条不同途径,即腺瘤 - 癌序列(ACS)和新发(DN)致癌作用。为阐明结直肠癌发生过程中的分子及临床病理特征,我们检查了30例腺瘤、30例腺瘤内癌(CIA)以及18例无任何腺瘤成分的早期单纯结直肠癌(EPC,即所谓的DN癌)的内镜切除标本,并比较了Fhit、Mlh1、Msh2、P53的表达及细胞表型(HGM、MUC2和CD10)。18例EPC中有8例(44%)Fhit表达明显降低或缺失,但腺瘤或CIA中均未出现(p<0.0001)。18例EPC中有6例(33%)Mlh1表达缺失,但腺瘤和CIA中少见(p = 0.008)。这种Fhit表达改变在黏膜下浸润癌(p = 0.001)、淋巴或静脉浸润癌(p = 0.0018)以及Mlh1表达改变的肿瘤中显著更高(p = 0.01)。EPC(39%)和CIA(27%)中P53过表达的发生率显著高于腺瘤(3.3%)(p<0.05)。腺瘤区和癌区的表型表达存在显著差异。此外,在CIA和EPC中,CD10阳性病例(53%)的P53过表达率显著高于CD10阴性病例(19%)(p = 0.04)。目前的研究结果表明,Fhit和Mlh1表达异常可能与DN致癌作用有关,而P53过表达和表型表达变化可能有助于结直肠前驱病变的恶性转化。